Telomir Pharmaceuticals (Telomir Pharmaceuticals) Net Income From Continuing Operations : $-18.84 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Telomir Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2024 was $-6.26 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was $-18.84 Mil.

Telomir Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Telomir Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Net Income From Continuing Operations Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Net Income From Continuing Operations

-0.14

-0.85

-13.07

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial				-0.48	-1.55	-1.71	-9.33	-6.26

Telomir Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.84 Mil.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024